MANE - CIK 0001827635
The table below shows Veradermics, Inc's cash flow statement line items across its last 2 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Operating cash flow | -$71.60M | -$23.69M |
| Capital expenditure | $24.00K | $0.00 |
| Investing cash flow | -$118.86M | $0.00 |
| Dividends paid | - | - |
| Stock buybacks | - | - |
| Financing cash flow | $159.14M | $60.48M |
Veradermics, Inc reported operating cash flow of -$71.60M for fiscal year 2025. That is down 202.3% from -$23.69M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.